

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Tangible Materials Available for Licensing](#)

[Refer a Patient](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

CAMA-1 cells have an in-frame mutation in the E-cadherin gene, resulting in a truncated, non-functional protein. In addition, they have oncogenic mutations in PTEN and p53 and amplification of the cyclin D1 gene.

Source

This cell line was established in 1975 from the pleural effusion of a 51-year-old Caucasian female with malignant adenocarcinoma of the breast.

Inventors

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

Fogh J et al. (1977) Absence of HeLa cell contamination in 169 cell lines derived from human

tumors. *Journal of the National Cancer Institute* 58: 209-214 (PubMed ID: [833871](#))

Ji H et al. (1994) Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. *Journal of Cellular Biochemistry* 54: 332-342 (PubMed ID: [8200913](#))

van Horssen R et al. (2012) E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells. *Breast Cancer Research and Treatment* 136: 365-377 (PubMed ID: [23053649](#))

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK's ATCC Express License, see [here](#) for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see [here](#). Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.

Commercial License: Contact MSK's Tangible Materials team at TRMOTDRTM@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, [646-888-2354](tel:646-888-2354), weisgarf@mskcc.org.

Stage of Development

Ready to use

Indications

[Cancer](#) › [Breast](#)

Types

[Research Tools](#) › [Cell Lines](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center